DK2915529T3 - Terapeutisk regenerering og berigelse af okulær overfladesmøring - Google Patents

Terapeutisk regenerering og berigelse af okulær overfladesmøring Download PDF

Info

Publication number
DK2915529T3
DK2915529T3 DK15151634.1T DK15151634T DK2915529T3 DK 2915529 T3 DK2915529 T3 DK 2915529T3 DK 15151634 T DK15151634 T DK 15151634T DK 2915529 T3 DK2915529 T3 DK 2915529T3
Authority
DK
Denmark
Prior art keywords
prg4
pharmaceutical composition
thr
pro
lys
Prior art date
Application number
DK15151634.1T
Other languages
English (en)
Inventor
Benjamin Sullivan
Tannin A Schmidt
David A Sullivan
Original Assignee
Univ California
Schepens Eye Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Schepens Eye Res Inst filed Critical Univ California
Application granted granted Critical
Publication of DK2915529T3 publication Critical patent/DK2915529T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Eyeglasses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (16)

1. Farmaceutisk sammensætning omfattende PRG4, eller et smørefragment deraf, til anvendelse i behandlingen, med topikal anvendelse på den okulære overflade, af en mangel på okulær smøring eller symptomer associeret dermed.
2. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning omfattende PRG4, eller et smørefragment deraf, er administreret i kombination med en for øjnene acceptabel formulering omfattende et eller flere for øjnene acceptable stoffer valgt fra gruppen bestående af et for øjnene acceptabelt lindrende middel, en for øjnene acceptabel excipiens, et for øjnene acceptabelt sammensnerpende middel, et for øjnene acceptabelt karforsnævrende middel, et for øjnene acceptabelt blødgøringsmiddel, og en for øjnene acceptabel elektrolyt.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning omfattende PRG4, eller et smørefragment deraf, er administreret i kombination med en for øjnene acceptabel opløsning omfattende en terapeutisk effektiv koncentration af natriumhyaluronat eller hyaluronsyre.
4. Farmaceutisk sammensætning til anvendelse ifølge krav 3, hvor den for øjnene acceptable opløsning omfatter natriumhyaluronat eller hyaluronsyre i den terapeutisk effektive koncentration på 10-100.000 pg/mL.
5. Farmaceutisk sammensætning til anvendelse ifølge krav 3, hvor den for øjnene acceptable opløsning omfatter natriumhyaluronat eller hyaluronsyre i den terapeutisk effektive koncentration på 500-5.000 pg/mL.
6. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning omfattende PRG4, eller et smørefragment deraf, er administreret i kombination med en for øjnene acceptabel opløsning omfattende en terapeutisk effektiv koncentration af et overfladeaktivt phospholipid valgt fra gruppen bestående af L-a-dipalmitoylphosphatidylcholin, phosphatidylcholin, phosphatidylethanolamin og sphingomyelin.
7. Farmaceutisk sammensætning til anvendelse ifølge krav 6, hvor den for øjnene acceptable opløsning omfatter det overfladeaktive phospholipid i den terapeutisk effektive koncentration på 10-10.000 pg/mL.
8. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning omfattende PRG4, eller et smørefragment deraf, er administreret i kombination med en phosphat-bufferet saltopløsning omfattende mindst natriumphosphat og natriumchlorid.
9. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning omfattende PRG4, eller et smørefragment deraf, er administreret i kombination med en for øjnene acceptabel balanceret saltopløsning omfattende en eller flere elektrolytter valgt fra gruppen bestående af kaliumchlorid, natriumbicarbonat, kaliumbicarbonat, calciumchlorid, magnesiumchlorid, trinatriumcitrat, saltsyre og natriumhydroxid.
10. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor PRG4, eller smørefragmentet deraf er et rekombinant PRG4-protein, eller smørefragment deraf.
11. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor PRG4 er et oprenset naturligt forekommende PRG4-protein.
12. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning omfattende PRG4, eller et smørefragment deraf, er administreret i kombination med en for øjnene acceptabel opløsning omfattende en terapeutisk effektiv koncentration af natriumhyaluronat eller hyaluronsyre, og et overfladeaktivt phospholipid valgt fra gruppen bestående af L-α-dipalmitoylphosphatidylcholin, phosphatidylcholin, phosphatidylethanolamin og sphingomyelin.
13. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor manglen på okulær smøring er forårsaget af vandig eller fordampende tørre øjne sygdom, Sjogrens syndrom, keratoconjunctivitis sicca, androgenmangel, meibomsk kirtelsygdom, østrogenerstatningsterapi, kontaktlinseslid, refraktionskirurgi, allergi, reduceret tårefilms brudtid, kompromitteret tårefilm, allergi, okulær overfladelidelser, øgede proteaseniveauer i tårefilmen og ved den okulære overflade, kronisk inflammation, hyperosmolaritet, aldring, eller kombinationer deraf.
14. Farmaceutisk sammensætning egnet til topikal påføring til en okulær overflade omfattende en terapeutisk effektiv koncentration af PRG4, eller et smørefragment deraf, opslæmmet i en for øjnene acceptabel balanceret saltopløsning.
15. Farmaceutisk sammensætning, til anvendelse ifølge krav 1, eller den farmaceutiske sammensætning ifølge krav 14, hvor smørefragmentet af PRG4 omfatter færre gentagelser inden for det centrale mucin-lignende KEPAPTT-gentagelsesdomæne (SEQ ID N0:4).
16. Farmaceutisk sammensætning til anvendelse ifølge krav 1, hvor den farmaceutiske sammensætning omfatter PRG4, eller et smørefragment deraf, i en koncentration på 50-500 pg/mL.
DK15151634.1T 2008-05-07 2009-04-08 Terapeutisk regenerering og berigelse af okulær overfladesmøring DK2915529T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5111208P 2008-05-07 2008-05-07
EP09743204.1A EP2285364B1 (en) 2008-05-07 2009-04-08 Therapeutic replenishment and enrichment of ocular surface lubrication

Publications (1)

Publication Number Publication Date
DK2915529T3 true DK2915529T3 (da) 2017-08-07

Family

ID=41264988

Family Applications (3)

Application Number Title Priority Date Filing Date
DK15151634.1T DK2915529T3 (da) 2008-05-07 2009-04-08 Terapeutisk regenerering og berigelse af okulær overfladesmøring
DK09743204.1T DK2285364T3 (da) 2008-05-07 2009-04-08 Terapeutisk regenerering og berigelse af okulær overfladesmøring
DK09743588.7T DK2276496T3 (da) 2008-05-07 2009-05-06 Terapeutisk modulering af øjenoverfladebefugtning

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK09743204.1T DK2285364T3 (da) 2008-05-07 2009-04-08 Terapeutisk regenerering og berigelse af okulær overfladesmøring
DK09743588.7T DK2276496T3 (da) 2008-05-07 2009-05-06 Terapeutisk modulering af øjenoverfladebefugtning

Country Status (16)

Country Link
US (9) US9393285B2 (da)
EP (4) EP2285364B1 (da)
JP (3) JP5508398B2 (da)
CN (2) CN102164593B (da)
CA (3) CA2722913C (da)
CY (2) CY1119122T1 (da)
DK (3) DK2915529T3 (da)
ES (3) ES2633792T3 (da)
HR (3) HRP20150097T1 (da)
HU (2) HUE024146T2 (da)
LT (2) LT2915529T (da)
PL (3) PL2285364T3 (da)
PT (2) PT2915529T (da)
RU (1) RU2510274C2 (da)
SI (3) SI2285364T1 (da)
WO (3) WO2009137217A2 (da)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US9884038B2 (en) 2004-06-07 2018-02-06 University Of Tennessee Research Foundation Selective androgen receptor modulator and methods of use thereof
US20090043365A1 (en) * 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US8083787B2 (en) 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
US7981095B2 (en) 2005-07-18 2011-07-19 Tearscience, Inc. Methods for treating meibomian gland dysfunction employing fluid jet
US8950405B2 (en) 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US7981146B2 (en) 2006-05-15 2011-07-19 Tearscience Inc. Inner eyelid treatment for treating meibomian gland dysfunction
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US7981147B2 (en) 2006-05-15 2011-07-19 Tearscience, Inc. Outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8128673B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US7976573B2 (en) 2006-05-15 2011-07-12 Tearscience, Inc. Inner eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8137390B2 (en) 2006-05-15 2012-03-20 Tearscience, Inc. System for providing heat treatment and heat loss reduction for treating meibomian gland dysfunction
US8128674B2 (en) 2006-05-15 2012-03-06 Tearscience, Inc. System for outer eyelid heat and pressure treatment for treating meibomian gland dysfunction
US8007524B2 (en) 2006-05-15 2011-08-30 Tearscience, Inc. Heat treatment and heat loss reduction for treating meibomian gland dysfunction
US7968603B2 (en) 2007-09-11 2011-06-28 University Of Tennessee Research Foundation Solid forms of selective androgen receptor modulators
US8506944B2 (en) 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication
HUE024146T2 (en) 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication
WO2009143865A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2009143864A1 (en) 2008-05-30 2009-12-03 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory digestive diseases
WO2010072228A1 (en) 2008-12-22 2010-07-01 Xigen S.A. Novel transporter constructs and transporter cargo conjugate molecules
JP2012527485A (ja) 2009-05-22 2012-11-08 ルブリス，エルエルシー． Ｐｒｇ４及びその治療調節作用の応用及び使用
US8791158B2 (en) 2010-01-11 2014-07-29 Gtx, Inc. Methods of treating meibomian gland dysfunction
WO2011160653A1 (en) 2010-06-21 2011-12-29 Xigen S.A. Novel jnk inhibitor molecules
WO2012048721A1 (en) 2010-10-14 2012-04-19 Xigen S.A. Use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of chronic or non-chronic inflammatory eye diseases
WO2012174123A1 (en) * 2011-06-13 2012-12-20 Allergan, Inc. Treatment of psychological trauma
BR112013034051A2 (pt) * 2011-06-29 2019-09-24 Allergan Inc formulações de macrogol 15 hidroxiestearato
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
JP2015500213A (ja) * 2011-11-30 2015-01-05 ザイジェン インフラメーション リミテッド 眼乾燥症候群を処置するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (en) 2011-12-21 2013-06-27 Xigen S.A. Novel jnk inhibitor molecules for treatment of various diseases
US9827250B2 (en) * 2012-07-31 2017-11-28 Johnson & Johnson Vision Care, Inc. Lens incorporating myopia control optics and muscarinic agents
WO2014031857A2 (en) 2012-08-22 2014-02-27 Tearscience, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9763827B2 (en) 2013-04-30 2017-09-19 Tear Film Innovations, Inc. Systems and methods for the treatment of eye conditions
EP3424558B1 (en) 2013-04-30 2020-07-22 Alcon Inc. Systems for the treatment of eye conditions
KR20160023669A (ko) 2013-06-26 2016-03-03 자이겐 인플라메이션 리미티드 다양한 질병의 치료를 위한 jnk 신호 전달 경로의 세포 투과성 펩타이드 억제자의 새로운 용도
WO2014206427A1 (en) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. New use of cell-permeable peptide inhibitors of the jnk signal transduction pathway for the treatment of various diseases
WO2015197097A1 (en) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. New use for jnk inhibitor molecules for treatment of various diseases
WO2015060935A1 (en) 2013-10-22 2015-04-30 Lubris, Llc Control of rheological properties of mixed hyaluronate/lubricin solutions
US9668916B2 (en) 2013-11-04 2017-06-06 Vance M. Thompson Conjunctival cover and methods therefor
US20150141328A1 (en) * 2013-11-18 2015-05-21 The Schepens Eye Research Institute Stimulation of human meibomian gland function
AU2014354859B2 (en) 2013-11-26 2020-04-09 Lubris Llc Compositions and methods for inhibiting intercellular interactions
EP3154413B1 (en) * 2014-06-15 2021-08-25 Yeda Research and Development Co. Ltd. Surface treatment of contact lens and treatment of ocular discomfort by water soluble polymers and lipids/liposomes
IL234929B (en) * 2014-10-01 2021-01-31 Yeda Res & Dev Liposomes-containing antifouling compositions and uses thereof
US9395557B2 (en) 2014-11-12 2016-07-19 Vance M. Thompson Partial corneal conjunctival contact lens
AU2016211694B2 (en) * 2015-01-26 2021-11-11 Lubris Llc Use of PRG4 as an anti-inflammatory agent
US9869883B2 (en) 2015-03-11 2018-01-16 Vance M. Thompson Tear shaping for refractive correction
HK1243349A1 (en) * 2015-04-03 2018-07-13 Santen Pharmaceutical Co., Ltd. Dry eye therapeutic agent having as active ingredient nandrolone or ester thereof or methenolone or ester thereof
WO2016187414A1 (en) * 2015-05-19 2016-11-24 Lubris Llc Use of prg4 to improve dynamic visual acuity and higher order aberrations
JP6718608B2 (ja) * 2016-05-25 2020-07-08 国立大学法人愛媛大学 眼表面・眼瞼摩擦係数測定装置および眼表面・眼瞼摩擦係数評価方法
US10974063B2 (en) 2016-06-30 2021-04-13 Alcon Inc. Light therapy for eyelash growth
US10353220B2 (en) 2016-10-17 2019-07-16 Vance M. Thompson Tear shaping for refractive correction
US10678067B2 (en) 2018-04-06 2020-06-09 Vance M. Thompson Tear shaping for refractive correction
MX2020013869A (es) * 2018-06-21 2021-03-02 Lubris Llc Lubricina para uso en curacion de heridas referencia cruzada con solicitudes relacionadas.
WO2020097345A1 (en) * 2018-11-08 2020-05-14 The Schepens Eye Research Institute, Inc. Therapeutic approaches for tissue reconstruction and wound healing treatment
WO2020130147A1 (ja) 2018-12-21 2020-06-25 国立大学法人京都大学 ルブリシン局在軟骨様組織、その製造方法及びそれを含む関節軟骨損傷治療用組成物
JP7667569B2 (ja) * 2019-01-15 2025-04-23 コーネル ユニバーシティー 組換えラブリシン、並びにそれを使用するための組成物及び方法
EP4003225A4 (en) * 2019-07-26 2023-05-31 Pandorum Technologies Private Limited BIOLOGICAL INK FORMULATIONS, BIO-PRINTED LENTICULUS AND RELATED APPLICATIONS
US20220347167A1 (en) * 2019-10-05 2022-11-03 The Schepens Eye Research Institute, Inc. A new treatment for meibomian gland dysfunction
US11609438B2 (en) * 2019-10-31 2023-03-21 Menicon Singapore Pte Ltd. Ocular lens with friction control structures

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550022A (en) * 1981-10-05 1985-10-29 Alcon Laboratories, Inc. Tissue irrigating solution
SE8501723L (sv) * 1985-04-09 1986-10-10 Pharmacia Ab Preparation att anvendas vid behandling av ledinflammation
US4964206A (en) * 1988-03-15 1990-10-23 Minnesota Mining And Manufacturing Company Intraocular lens anchoring filament to lens element fixation method
US4964205A (en) * 1988-06-13 1990-10-23 Rampart Packaging Inc. Method for making screw cap jar
US5326558A (en) 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
US6433142B1 (en) 1989-08-08 2002-08-13 Genetics Institute, Llc Megakaryocyte stimulating factors
RU2033165C1 (ru) * 1989-10-13 1995-04-20 Межотраслевой научно-технический комплекс "Микрохирургия глаза" Способ получения пластичного материала из коллагена
JPH07508716A (ja) 1992-04-21 1995-09-28 ザ　スキーペンズ　アイ　リサーチ　インスティテュート，インコーポレイテッド シェーグレン症候群における眼のアンドロゲン療法
US6107289A (en) * 1992-04-21 2000-08-22 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens or TGF-β
US5688765A (en) 1992-04-21 1997-11-18 The Schepens Eye Research Institute, Inc. Ocular therapy in Sjogren's syndrome using topically applied androgensor TGF-β
IL106922A (en) * 1992-09-14 1998-08-16 Novartis Ag Composite materials with one or more wettable surfaces and process for their preparation
US5351100A (en) * 1992-12-09 1994-09-27 Bmc Industries, Inc. Glass multifocal ophthalmic lens with polarizing element and method of making
JPH09505057A (ja) * 1993-11-19 1997-05-20 ザ・ユニバーシティ・オブ・シドニー 白内障を予防または制御するための方法
US5515590A (en) * 1994-07-19 1996-05-14 University Of Kentucky Research Foundation Method for reducing the generation of wear particulates from an implant
US5518732A (en) * 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
DE69629230D1 (de) * 1995-03-24 2003-09-04 Ocular Res Of Bonton Inc Hydrogellinse mit Lipid-Vorbeschichtigung
RU2207885C2 (ru) * 1995-08-30 2003-07-10 Фармация Аб Способ подачи небольшого объема лечебного раствора к целевому месту
US6689748B1 (en) * 1998-04-08 2004-02-10 Theoharis C. Theoharides Method of treating mast cell activation-induced diseases with a proteoglycan
WO2000027421A2 (en) * 1998-11-06 2000-05-18 The Schepens Eye Research Institute, Inc. LOCAL USE OF SOLUBLE TUMOR NECROSIS RECEPTOR I (sTNFRI) FOR PROPHYLAXIS AND TREATMENT OF CORNEAL TRANSPLANT REJECTION AND OTHER DISORDERS OF THE EYE
JP4551563B2 (ja) * 1998-11-10 2010-09-29 電気化学工業株式会社 ヒアルロン酸ゲルの製造方法及び医用材料
US6743774B1 (en) 1999-04-23 2004-06-01 Rhode Island Hospital Tribonectins
US6960562B2 (en) 1999-04-23 2005-11-01 Rhode Island Hospital, A Lifespan Partner Tribonectin polypeptides and uses thereof
JP4755795B2 (ja) * 2000-02-03 2011-08-24 電気化学工業株式会社 ヒアルロン酸ゲルの製造方法及びそれを含有する医用材料
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
AU2002239601B2 (en) * 2000-12-20 2005-09-01 Alcon Inc. Intraocular irrigating solution having improved flow characteristics
AU2002232437A1 (en) * 2000-12-20 2002-07-01 Alcon Universal Ltd. Ophthalmic lubricating solution adapted for use in lasik surgery
JP2004529929A (ja) * 2001-04-23 2004-09-30 ニュクリスト ファーマシューティカルズ コーポレーション アポトーシスの誘導およびマトリックスメタロプロテイナーゼの阻害のための金属の使用
US6815074B2 (en) * 2001-05-30 2004-11-09 Novartis Ag Polymeric materials for making contact lenses
CN1980582B (zh) * 2001-08-17 2010-12-22 美你康株式会社 用于用后即弃式软隐形眼镜的包装
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
AR038269A1 (es) * 2002-01-09 2005-01-12 Novartis Ag Articulos polimericos que tienen un recubrimiento lubrico, y metodo para fabricarlos
TW200304385A (en) * 2002-03-13 2003-10-01 Novartis Ag Materials containing multiple layers of vesicles
SE0201479D0 (sv) * 2002-05-16 2002-05-16 Pharmacia Groningen Bv Kit and method in eye surgery
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
WO2005013939A1 (en) * 2003-08-06 2005-02-17 Nirmal Mulye Pharmaceutical composition containing water soluble drug
CN1867350A (zh) * 2003-08-14 2006-11-22 惠氏公司 重组润滑素分子及其用途
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
WO2005027933A1 (en) 2003-09-23 2005-03-31 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Unsaturated phosphatidylcholines and uses thereof
EP1740190A1 (de) * 2004-03-05 2007-01-10 Synthes GmbH Verwendung eines gemisches für die herstellung eines mittels zur behandlung von defektem oder degeneriertem knorpel in vivo und bei der herstellung von natürlichem knorpelersatz in vitro
US20090060933A1 (en) * 2004-06-14 2009-03-05 Estell David A Proteases producing an altered immunogenic response and methods of making and using the same
US20050287223A1 (en) * 2004-06-23 2005-12-29 Peyman Gholam A Use of amniotic membrane as biocompatible devices
WO2006088491A2 (en) * 2004-06-29 2006-08-24 Massachusetts Institute Of Technology Methods and compositions related to the modulation of intercellular junctions
JP2008507553A (ja) * 2004-07-23 2008-03-13 ミューコサル セラピューティクス リミテッド ライアビリディ カンパニー 粘性補給のための組成物および方法
US7662509B2 (en) * 2004-10-29 2010-02-16 Medtronic, Inc. Lithium-ion battery
CN101252936A (zh) * 2005-03-02 2008-08-27 奈森特医药公司 眼用组合物的药学可接受的载体
DK2444079T3 (da) * 2005-05-17 2017-01-30 Sarcode Bioscience Inc Sammensætninger og fremgangsmåder til behandling af øjensygdomme
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
JP5549045B2 (ja) * 2006-01-13 2014-07-16 大正製薬株式会社 蒸発亢進型ドライアイの予防又は改善用水性点眼剤
US20080094573A1 (en) * 2006-04-04 2008-04-24 Vermette Patrick Surface-modified materials, such as contact lenses, methods and kits for their preparation, and uses thereof
US9539202B2 (en) * 2006-04-28 2017-01-10 Universidad Complutense De Madrid Formulation of liposomal vesicles in aqueous solutions with lachrymal film characteristics
US20070264226A1 (en) * 2006-05-10 2007-11-15 Karagoezian Hampar L Synergistically enhanced disinfecting solutions
ES2581765T3 (es) * 2006-08-24 2016-09-07 University Of Tennessee Research Foundation Acilanilidas sustituidas y métodos de uso de las mismas
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
US20080197324A1 (en) * 2007-02-20 2008-08-21 Fang Zhao Ophthalmic composition containing a polyol-acid copolymer
US20090068247A1 (en) 2007-09-12 2009-03-12 Mucosal Therapeutics Biocompatible devices coated with a tribonectin and methods for their production
US7780879B2 (en) 2007-12-20 2010-08-24 Novartis Ag Method for making contact lenses
HUE024146T2 (en) * 2008-05-07 2016-02-29 Univ California Medical filling and enrichment of eye surface lubrication
US8506944B2 (en) * 2008-05-07 2013-08-13 The Regents Of The University Of California Replenishment and enrichment of ocular surface lubrication

Also Published As

Publication number Publication date
HRP20191732T1 (hr) 2019-12-13
JP2011519933A (ja) 2011-07-14
WO2009137217A3 (en) 2009-12-30
HRP20150097T1 (hr) 2015-03-27
US9585936B2 (en) 2017-03-07
US9393285B2 (en) 2016-07-19
US9248161B2 (en) 2016-02-02
US20110070222A1 (en) 2011-03-24
EP2276496A1 (en) 2011-01-26
US20140296159A1 (en) 2014-10-02
JP5474054B2 (ja) 2014-04-16
SI2276496T1 (sl) 2019-11-29
JP2011519949A (ja) 2011-07-14
US20160101149A1 (en) 2016-04-14
EP2285364A4 (en) 2011-07-20
PL2915529T3 (pl) 2017-10-31
US20110142908A1 (en) 2011-06-16
EP2276497A1 (en) 2011-01-26
CA2722944A1 (en) 2009-11-12
SI2915529T1 (sl) 2017-09-29
US20180028598A1 (en) 2018-02-01
PT2915529T (pt) 2017-07-24
WO2009137217A8 (en) 2010-12-09
US9730978B2 (en) 2017-08-15
PL2276496T3 (pl) 2020-01-31
JP5508398B2 (ja) 2014-05-28
US20160235809A1 (en) 2016-08-18
RU2510274C2 (ru) 2014-03-27
US8563028B2 (en) 2013-10-22
EP2276496B1 (en) 2019-07-10
EP2915529B1 (en) 2017-06-14
CN102164593A (zh) 2011-08-24
US9421241B2 (en) 2016-08-23
EP2915529A1 (en) 2015-09-09
PT2285364E (pt) 2015-02-24
CA2722913C (en) 2018-02-27
EP2276496A4 (en) 2011-08-17
WO2009137602A1 (en) 2009-11-12
SI2285364T1 (sl) 2015-03-31
CY1119122T1 (el) 2018-02-14
JP5439652B2 (ja) 2014-03-12
US8945604B2 (en) 2015-02-03
CA2723144C (en) 2018-05-22
US20110059902A1 (en) 2011-03-10
WO2009137217A2 (en) 2009-11-12
EP2285364A2 (en) 2011-02-23
CA2723144A1 (en) 2009-11-12
US20160015780A1 (en) 2016-01-21
PL2285364T3 (pl) 2015-04-30
DK2285364T3 (da) 2015-02-16
CN105664136A (zh) 2016-06-15
HRP20171079T1 (hr) 2017-10-06
WO2009137603A1 (en) 2009-11-12
US20140099343A1 (en) 2014-04-10
EP2276497B1 (en) 2020-04-22
LT2276496T (lt) 2019-10-25
JP2011520812A (ja) 2011-07-21
ES2748139T3 (es) 2020-03-13
HUE024146T2 (en) 2016-02-29
CY1122638T1 (el) 2021-03-12
EP2285364B1 (en) 2015-01-21
CA2722913A1 (en) 2009-11-12
ES2633792T3 (es) 2017-09-25
DK2276496T3 (da) 2019-10-07
ES2530723T3 (es) 2015-03-04
HUE045686T2 (hu) 2020-01-28
CN102164593B (zh) 2016-02-03
US9138457B2 (en) 2015-09-22
LT2915529T (lt) 2018-10-25
RU2010147935A (ru) 2012-06-20
EP2276497A4 (en) 2011-12-21

Similar Documents

Publication Publication Date Title
DK2915529T3 (da) Terapeutisk regenerering og berigelse af okulær overfladesmøring
US8506944B2 (en) Replenishment and enrichment of ocular surface lubrication
US20200368328A1 (en) Compostions for Treating Dry Eye Disease